The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans.

Barnes PJ, Dixon CM

The American review of respiratory disease1 Aug 1984Cited by 59 (Europe PMC)

PMID6465669DOI10.1164/arrd.1984.130.2.162PepBankPUB-06465669

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In atopic asthmatic subjects, specific airway conductance did not change after inhaled VIP or control.
In plain wordsIn people with allergic asthma, inhaled VIP did not change airway openness compared with control.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeSpecific airway conductance (SGaw)
Study
n = 6
Comparator
Control solution (diluent)
Outcome group
Respiratory function · Respiratory
Studied dose
100 micrograms · inhalationAs given in this study (human).
Source sentences
Summary
Specific airway conductance (SGaw) did not change after control or VIP inhalations
1 context sentence(design, population, supporting numbers)
Summary · context
We have investigated the effect of VIP on bronchomotor tone and bronchial responsiveness to inhaled histamine in 6 atopic asthmatic subjects.
Report a problemFND-0646566901
02HumanRandomized controlled trialEfficacy outcome
In atopic asthmatic subjects, inhaled VIP significantly increased the histamine concentration needed to cause a 35% fall in SGaw, while control did not.
In plain wordsIn people with allergic asthma, inhaled VIP made the airways less sensitive to histamine, while control did not.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseBronchial reactivity to histamine (PC35)
Study
n = 6
Comparator
Control solution (diluent)
Outcome group
Respiratory function · Respiratory
Studied dose
100 micrograms · inhalationAs given in this study (human).
Measurements
PC35
2.18 mg/ml
before VIP
PC35
5 mg/ml
after VIP
Source sentences
Summary
significantly increased after VIP (from 2.18 +/- 1.04 to 5.00 +/- 2.31 mg/ml histamine, mean +/- SE; p less than 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
We have investigated the effect of VIP on bronchomotor tone and bronchial responsiveness to inhaled histamine in 6 atopic asthmatic subjects.
Report a problemFND-0646566902
03HumanRandomized controlled trialEfficacy outcome
In atopic asthmatic subjects, the increase in PC35 after inhaled VIP was significantly smaller than after salbutamol.
In plain wordsIn people with allergic asthma, inhaled VIP protected against histamine less than salbutamol did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseBronchial reactivity to histamine compared with salbutamol
Study
n = 6
Comparator
Salbutamol
Outcome group
Respiratory function · Respiratory
Studied dose
100 micrograms · inhalationAs given in this study (human).
Source sentences
Summary
the increase after salbutamol being significantly greater than after VIP.
1 context sentence(design, population, supporting numbers)
Summary · context
We have investigated the effect of VIP on bronchomotor tone and bronchial responsiveness to inhaled histamine in 6 atopic asthmatic subjects.
Report a problemFND-0646566903
04HumanRandomized controlled trialSafety outcome
In atopic asthmatic subjects, no change in heart rate was found after inhaled VIP.
In plain wordsIn people with allergic asthma, inhaled VIP did not change heart rate.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeHeart rate
Study
n = 6
Comparator
Control solution (diluent)
Outcome group
Heart function · Cardiovascular
Studied dose
100 micrograms · inhalationAs given in this study (human).
Source sentences
Summary
No changes in heart rate or blood pressure were found after any inhalation.
1 context sentence(design, population, supporting numbers)
Summary · context
We have investigated the effect of VIP on bronchomotor tone and bronchial responsiveness to inhaled histamine in 6 atopic asthmatic subjects.
Report a problemFND-0646566904
05HumanRandomized controlled trialSafety outcome
In atopic asthmatic subjects, no change in blood pressure was found after inhaled VIP.
In plain wordsIn people with allergic asthma, inhaled VIP did not change blood pressure.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeBlood pressure
Study
n = 6
Comparator
Control solution (diluent)
Outcome group
Blood pressure · Cardiovascular
Studied dose
100 micrograms · inhalationAs given in this study (human).
Source sentences
Summary
No changes in heart rate or blood pressure were found after any inhalation.
1 context sentence(design, population, supporting numbers)
Summary · context
We have investigated the effect of VIP on bronchomotor tone and bronchial responsiveness to inhaled histamine in 6 atopic asthmatic subjects.
Report a problemFND-0646566905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.